• CCR7–Notch1 Crosstalk and Mammary Cancer Stemness

  2026-10-07

  Boyle et al. reported that CCR7 signaling functionally intersects with Notch1 activity in stem-like cells derived from MMTV-PyMT mammary tumors. The study links receptor signaling to cleaved Notch1 and stem-like behavior, while its cell-based, mouse-model design supports mechanistic interpretation but does not establish clinical efficacy or therapeutic safety.

• Obeticholic Acid: FXR Evidence and Limits

  2026-10-07

  A source-grounded overview of Obeticholic Acid as an FXR agonist, distinguishing vendor-described bile acid biology from peer-reviewed findings on 11β-HSD1 inhibition in mouse liver fibrosis research.

• Cy5 TSA Fluorescence System Kit: Evidence in HCC

  2026-10-06

  A source-grounded overview of tyramide signal amplification in cancer research, using the miR-3180 hepatocellular carcinoma study to distinguish biological findings from supplier-reported fluorescence performance and to define the method’s evidence boundaries.

• EZ Cap™ Cas9 mRNA: Reading Causal Evidence

  2026-10-06

  EZ Cap™ Cas9 mRNA (5-moUTP) can be understood not only as a genome editing reagent, but also as a tool for testing causal models in functional gene studies. This article examines how its molecular design could complement, rather than replace, the mechanistic evidence from a zebrafish Fyn–Stat3 neurodegeneration study.

• Obeticholic Acid: Evidence, Scope, and Limits

  2026-10-05

  A source-grounded overview of Obeticholic Acid, FXR biology, the strength of available evidence, and why findings from a separate 11β-HSD1 mouse study should not be attributed to this compound.

• Cy5 NHS Ester(Et): Product Overview

  2026-10-05

  Cy5 NHS ester(Et) is a supplier-described fluorescent dye reagent for conceptual amino-group labeling of biomolecules. No matched peer-reviewed paper evidence was provided, so performance and application claims remain unvalidated here.

• Acetoacetic Acid Sodium Salt: Evidence and Limits

  2026-10-04

  A source-grounded overview of acetoacetic acid sodium salt, covering its chemical identity, metabolic interpretation, evidence quality, research scope, and limitations in diabetes and ketone body research.

• Oseltamivir Acid: Evidence and Research Context

  2026-10-03

  Oseltamivir acid is the active neuraminidase-inhibiting metabolite of oseltamivir phosphate. This overview compares its established influenza pharmacology with exploratory oncology claims, resistance evidence, translational questions, and important limits on interpreting supplier-reported data.

• WAY-100635: From Binding to Pain-Affect Causality

  2026-10-01

  WAY-100635 is a selective 5-HT1A antagonist for separating receptor binding from sensory, affective, and serotonergic outcomes. This article develops a causal assay framework inspired by recent cannabidiol pain research rather than repeating a conventional workflow guide.

• Meropenem in Infection and Resistance Research

  2026-10-01

  Meropenem provides a practical β-lactam antibiotic carbapenem platform for MIC, time-kill, resistance, and infection-model studies. This guide connects its PBP-driven activity with exposure-aware assay design, formulation comparisons, and troubleshooting for reproducible preclinical workflows.

• Cefotaxime: From Mechanism to AMR Strategy

  2026-09-30

  Cefotaxime is more than a broad-spectrum selection reagent: it can serve as a mechanistic probe for cell-wall targeting, beta-lactamase activity, and resistance architecture. This thought-leadership guide connects its use in bacterial infection models with findings from a 2025 multicenter study of carbapenem-resistant Enterobacter cloacae, offering translational researchers a framework for linking phenotype, genotype, plasmid mobility, and epidemiology without overstating what any single antibiotic readout can prove.

• Coumestrol in RA: ER Antagonism and Ferroptosis

  2026-09-30

  Coumestrol is a phytoestrogen estrogen receptor antagonist with reported nanomolar activity at ERα and ERβ. In rheumatoid arthritis fibroblast-like synoviocytes, a 2026 study linked Coumestrol treatment to PMAIP1-dependent ferroptosis, reduced proliferation, and lower inflammatory signaling.

• hiPSC Intestinal Organoids for Pharmacokinetic Studies

  2026-09-29

  Saito and colleagues developed a direct three-dimensional culture strategy for generating expandable intestinal organoids from human induced pluripotent stem cells. The resulting organoids can be propagated, cryopreserved, and differentiated into intestinal epithelial cells with enterocyte CYP and transporter activities relevant to oral drug absorption and metabolism.

• EdU Imaging Kits (Cy3) for NSCLC Assays

  2026-09-29

  EdU Imaging Kits (Cy3) provide denaturation-free Cy3 click labeling for precise S-phase measurements in cancer-cell experiments. Applied to NSCLC treatment studies, the workflow distinguishes reduced DNA synthesis from nonspecific cell loss and complements ferroptosis, viability, and molecular-pathway readouts.

• EdU Imaging Kits (Cy3) for CCA Proliferation

  2026-09-28

  EdU Imaging Kits (Cy3) convert S-phase DNA synthesis into a bright, denaturation-free Cy3 signal for microscopy or flow cytometry. The workflow provides a practical orthogonal readout for testing paeoniflorigenone, cisplatin, and HIF1A-linked proliferation changes in cholangiocarcinoma models.

8330 records 1/556 page Next 12345 下5页 Last page